Company Filing History:
Years Active: 2023-2025
Title: Monika Anna Papworth: Innovator in Therapeutic Polypeptides
Introduction
Monika Anna Papworth is a distinguished inventor based in Cambridge, GB. She has made significant contributions to the field of therapeutic polypeptides, holding a total of 3 patents. Her work focuses on innovative solutions for treating cardiovascular diseases and enhancing recombinant polypeptide therapeutics.
Latest Patents
One of her latest patents is titled "Heterodimeric Relaxin fusions and uses thereof." This invention relates to heterodimeric Relaxin fusion polypeptides, particularly heterodimeric Relaxin 2 fusion polypeptides. The invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions, and kits comprising the same. These innovations are particularly useful in the treatment of cardiovascular diseases, including heart failure.
Another notable patent is "Engineered O-glycosylation in recombinant polypeptides and uses thereof." This invention pertains to recombinant polypeptide therapeutics that have an engineered O-linked amino acid glycosylation sequence. These polypeptides can be produced in mammalian cells to present natural or un-natural O-glycan structures through metabolic labeling.
Career Highlights
Monika is currently associated with Medimmune Limited, where she continues to advance her research and development efforts in the field of biopharmaceuticals. Her work has been instrumental in creating innovative therapeutic solutions that address critical health issues.
Collaborations
Throughout her career, Monika has collaborated with notable colleagues, including Isabelle Sermadiras and Judy Christiane Paterson. These collaborations have further enriched her research and contributed to the success of her inventions.
Conclusion
Monika Anna Papworth is a prominent inventor whose work in therapeutic polypeptides has the potential to significantly impact the treatment of cardiovascular diseases. Her innovative patents and collaborations highlight her dedication to advancing medical science and improving patient outcomes.